Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Metabolic syndrome (MetS) is associated with nephropathy. Along with common risk factors such as hypertension and hyperglycemia, adipocytokines released from perirenal adipose tissue (PRAT) are implicated in the pathogenesis of MetS nephropathy. The study was designed to elucidate the adverse effects of PRAT-derived leptin on nephropathy and to determine whether the angiotensin II type 1 receptor antagonist telmisartan exerts a renoprotective effect by decreasing the PRAT-derived leptin level in the high-fat diet–induced MetS rat. In MetS rats, PRAT-derived leptin expression increased concomitant with dysfunction of adipogenesis, and the activities of the angiotensin II–angiotensin II type 1 receptor and the angiotensin-converting enzyme 2–angiotensin (1–7)–Mas receptor axes were imbalanced in PRAT. PRAT-derived leptin from MetS rats promoted proliferation of rat glomerular endothelial cells (GERs) by activating the p38 MAPK (mitogen-activated protein kinase) pathway, thereby contributing to the development of nephropathy. Long-term telmisartan treatment improved metabolic parameters and renal function, decreased the amount of PRAT, promoted adipogenesis, increased the expression of angiotensin-converting enzyme 2, restored balanced activities of the angiotensin II–AT1R and angiotensin-converting enzyme 2–angiotensin (1–7)–Mas axes, and exerted an indirect renoprotective effect on MetS rats by decreasing PRAT-derived leptin release. Our results demonstrate a novel link between nephropathy and PRAT in MetS and show that telmisartan confers an underlying protective effect on visceral adipose tissue and the kidney, suggesting that it has potential as a therapeutic agent for the treatment of MetS-associated nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Adipocytokines in Obesity and Metabolic Disease
Cao, H. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0339 · Cited by 705
Rajapurohitam, V., Javadov, S., Purdham, D. M., Kirshenbaum, L. A., & Karmazyn, M. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.05.001 · Cited by 102 · cited 1×
“In addition, a previous study by our group also showed that VAT-derived leptin from MetS rats stimulates phenotypic switching in vascular smooth muscle cells, even at a low concentration.(7) Therefore, it is reasonable to assume that a low local concentration of leptin can exacerbate nephropathy via a paracrine mechan…”
Result
Cited by
Obesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267
Self-citationImmunologic and endocrine functions of adipose tissue: implications for kidney disease
Zhu, Q., & Scherer, P. E. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.157 · Cited by 200
Cellular mechanisms underlying obesity-induced arterial stiffness
Aroor, A. R., Jia, G., & Sowers, J. R. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00235.2016 · Cited by 181
Metabolic syndrome-related kidney injury: a review and update
Lin, L., Tan, W., Pan, X., Tian, E., Wu, Z., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904001 · Cited by 139
“Animal studies have found that long-term administration of telmisartan can reduce the release of leptin from adipose tissue, thereby reducing proteinuria (125).”
BackgroundChen, X., Mao, Y., Hu, J., Han, S., Gong, L., Luo, T., Yang, S., Qing, H., Wang, Y., Du, Z., et al. (2021) · Diabetes · doi:10.2337/db20-1031 · Cited by 92
Self-citation
Metadata
- Authors
- Li, H., Li, M., Liu, P., Wang, Y., Zhang, H., Li, H., Yang, S., Song, Y., Yin, Y., Gao, L., Cheng, S., Cai, J., & Tian, G.
- Venue
- Hypertension
- Published
- 2016-08
- Volume
- 68
- Issue
- 2
- Pages
- 478-490
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2421190964
- Cited by
- 65
- References
- 3
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue. https://app.cochat.ai/papers/10.1161/hypertensionaha.116.07008
- The paper
- Li, H., Li, M., Liu, P., Wang, Y., Zhang, H., Li, H., Yang, S., Song, Y., Yin, Y., Gao, L., Cheng, S., Cai, J., & Tian, G. (2016). Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue. Hypertension. https://doi.org/10.1161/hypertensionaha.116.07008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.